文献速递淋巴瘤白血病MDS 与骨髓增殖性肿瘤

血管免疫母细胞性T细胞淋巴瘤中的克隆性造血及其向髓系肿瘤的分化演进

Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms.
PubMed 文献 · Blood Adv · 2020-01-01

该研究对22例T细胞淋巴瘤(TCL-TFH)患者的骨髓与组织标本及流式分选后的骨髓和外周血亚群进行综合基因组分析,发现15/22例(68%)患者的肿瘤性T细胞与髓系细胞存在相同突变,主要为TET2(14/15)和DNMT3A(10/15)。4例患者发生髓系肿瘤(MNs),均与TCL-TFH共享克隆性造血型突变,提示克隆性造血在TCL-TFH中普遍存在,且同一克隆可经分化演进分别形成TCL-TFH和MNs。

要点

  • 22例TCL-TFH中15例(68%)肿瘤性T细胞与髓系细胞检出相同突变。
  • 共享突变以TET2(14/15)和DNMT3A(10/15)为主。
  • 4例发生髓系肿瘤,均与TCL-TFH共享克隆性造血型突变。

核心结论

  • 克隆性造血在TCL-TFH患者中普遍存在,克隆性造血克隆的分化演进可同时形成TCL-TFH和髓系肿瘤。

研究设计与样本

  • 对22例TCL-TFH患者的配对骨髓与组织标本以及流式分选的骨髓和外周血亚群进行综合基因组研究。

主要发现

  • 22例TCL-TFH患者中15例(68%)的肿瘤性T细胞与髓系细胞检出相同突变,包括TET2(14/15)和DNMT3A(10/15)。
  • 4例患者发生髓系肿瘤,均与TCL-TFH共享克隆性造血型突变,且每例患者的TCL-TFH与髓系肿瘤还检出各自特有的遗传学改变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TET2 and DNMT3A mutations are frequently identified in T-cell lymphomas of T follicular helper cell origin (TCL-TFH), clonal hematopoiesis (CH), and myeloid neoplasms (MNs). The relationships among these 3 entities, however, are not well understood. We performed comprehensive genomic studies on paired bone marrow and tissue samples as well as on flow cytometry-sorted bone marrow and peripheral blood subpopulations from a cohort of 22 patients with TCL-TFH to identify shared CH-type mutations in various hematopoietic cell compartments. Identical mutations were detected in the neoplastic T-cell and myeloid compartments of 15 out of 22 patients (68%), including TET2 (14/15) and DNMT3A (10/15). Four patients developed MNs, all of which shared CH-type mutations with their TCL-TFH; additional unique genetic alterations were also detected in each patient's TCL-TFH and MN. These data demonstrate that CH is prevalent in patients with TCL-TFH and that divergent evolution of a CH clone may give rise to both TCL-TFH and MNs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lewis NE, Petrova-Drus K, Huet S, et al. Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Adv. 2020. PMID: 32442302. doi:10.1182/bloodadvances.2020001636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。